Can platelet-rich fibrin act as a natural carrier for antibiotics delivery? A proof-of-concept study for oral surgical procedures.
Antibiotics
Antimicrobial activity
Antimicrobial resistance
Drug delivery
Oral surgery
Platelet-rich fibrin
Journal
BMC oral health
ISSN: 1472-6831
Titre abrégé: BMC Oral Health
Pays: England
ID NLM: 101088684
Informations de publication
Date de publication:
09 03 2023
09 03 2023
Historique:
received:
12
12
2022
accepted:
13
02
2023
entrez:
9
3
2023
pubmed:
10
3
2023
medline:
14
3
2023
Statut:
epublish
Résumé
Evaluate the role of platelet-rich fibrin (PRF) as a natural carrier for antibiotics delivery through the analysis of drug release and antimicrobial activity. PRF was prepared according to the L-PRF (leukocyte- and platelet-rich fibrin) protocol. One tube was used as control (without drug), while an increasing amount of gentamicin (0.25 mg, G1; 0.5 mg, G2; 0.75 mg, G3; 1 mg, G4), linezolid (0.5 mg, L1; 1 mg, L2; 1.5 mg, L3; 2 mg, L4), vancomycin (1.25 mg, V1; 2.5 mg, V2; 3.75 mg, V3; 5 mg, V4) was added to the other tubes. At different times the supernatant was collected and analyzed. Strains of E. coli, P. aeruginosa, S. mitis, H. influenzae, S. pneumoniae, S. aureus were used to assess the antimicrobial effect of PRF membranes prepared with the same antibiotics and compared to control PRF. Vancomycin interfered with PRF formation. Gentamicin and linezolid did not change the physical properties of PRF and were released from membranes in the time intervals examined. The inhibition area analysis showed that control PRF had slight antibacterial activity against all tested microorganisms. Gentamicin-PRF had a massive antibacterial activity against all tested microorganisms. Results were similar for linezolid-PRF, except for its antibacterial activity against E. coli and P. aeruginosa that was comparable to control PRF. PRF loaded with antibiotics allowed the release of antimicrobial drugs in an effective concentration. Using PRF loaded with antibiotics after oral surgery may reduce the risk of post-operative infection, replace or enhance systemic antibiotic therapy while preserving the healing properties of PRF. Further studies are needed to prove that PRF loaded with antibiotics represents a topical antibiotic delivery tool for oral surgical procedures.
Identifiants
pubmed: 36894902
doi: 10.1186/s12903-023-02814-5
pii: 10.1186/s12903-023-02814-5
pmc: PMC9996939
doi:
Substances chimiques
Anti-Bacterial Agents
0
Vancomycin
6Q205EH1VU
Linezolid
ISQ9I6J12J
Anti-Infective Agents
0
Gentamicins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
134Informations de copyright
© 2023. The Author(s).
Références
J Clin Periodontol. 2019 Feb;46(2):241-247
pubmed: 30629300
Int J Oral Sci. 2020 Nov 26;12(1):32
pubmed: 33243983
Am J Clin Pathol. 1966 Apr;45(4):493-6
pubmed: 5325707
Clin Oral Investig. 2019 May;23(5):2179-2185
pubmed: 30280327
Clin Oral Investig. 2022 Aug;26(8):5281-5288
pubmed: 35451655
Sci Rep. 2017 Feb 02;7:41808
pubmed: 28150731
Clin Infect Dis. 2020 Jul 11;71(2):455-462
pubmed: 31728507
J Orthop Res. 2005 Jan;23(1):27-33
pubmed: 15607871
Clin Oral Investig. 2022 Aug;26(8):5429-5438
pubmed: 35501503
Tissue Eng Part B Rev. 2017 Feb;23(1):83-99
pubmed: 27672729
Biol Pharm Bull. 2000 Mar;23(3):371-4
pubmed: 10726900
Med Microbiol Immunol. 1975;161(1):23-39
pubmed: 236490
Acta Biomater. 2018 Jul 15;75:35-51
pubmed: 29772345
Transfusion. 1989 Jan;29(1):23-6
pubmed: 2911860
Biomaterials. 2003 Nov;24(24):4337-51
pubmed: 12922147
J Oral Implantol. 2014 Dec;40(6):679-89
pubmed: 24945603
Int J Mol Sci. 2021 Oct 26;22(21):
pubmed: 34768984
Oral Surg Oral Med Oral Pathol Oral Radiol. 2022 Oct;134(4):449-456
pubmed: 35718721
Platelets. 2016 Jun;27(4):276-85
pubmed: 26763769
Platelets. 2021 Apr 3;32(3):413-419
pubmed: 32306811
Trends Biotechnol. 2009 Mar;27(3):158-67
pubmed: 19187989
Int Wound J. 2016 Oct;13(5):1011-3
pubmed: 26369296
Expert Rev Anti Infect Ther. 2020 Dec;18(12):1245-1258
pubmed: 32684048
Clin Oral Investig. 2020 Mar;24(3):1171-1182
pubmed: 31321574
Clin Orthop Relat Res. 2007 Sep;462:200-6
pubmed: 17572634
J Control Release. 2008 Sep 24;130(3):202-15
pubmed: 18687500
Clin Oral Investig. 2020 May;24(5):1663-1675
pubmed: 31346783
Sci Rep. 2022 Feb 17;12(1):2710
pubmed: 35177676
Clin Oral Investig. 2021 Jun;25(6):3747-3755
pubmed: 33415379
Clin Oral Investig. 2021 May;25(5):2461-2478
pubmed: 33609186
Clin Infect Dis. 2014 Sep 1;59(5):698-705
pubmed: 24867792
Clin Oral Investig. 2022 Mar;26(3):2873-2878
pubmed: 34816309
Dermatol Ther. 2020 May;33(3):e13334
pubmed: 32219975
J Craniomaxillofac Surg. 2020 Mar;48(3):268-285
pubmed: 32063481
Clin Orthop Relat Res. 1996 Dec;(333):245-51
pubmed: 8981903
Int J Oral Implantol (Berl). 2019;12(1):77-87
pubmed: 31116189
Clin Oral Investig. 2020 Feb;24(2):1065-1072
pubmed: 31321573
Adv Drug Deliv Rev. 2014 Nov 30;78:14-27
pubmed: 25450262
J Antimicrob Chemother. 1996 Nov;38(5):829-37
pubmed: 8961052
Tissue Eng Part A. 2018 May;24(9-10):809-818
pubmed: 29096582
Am J Ophthalmol Case Rep. 2020 Aug 21;20:100838
pubmed: 32913920
J Bone Joint Surg Br. 2007 Mar;89(3):417-20
pubmed: 17356164
J Control Release. 2010 Nov 20;148(1):49-55
pubmed: 20637815
Platelets. 2019;30(3):329-340
pubmed: 29509050
PLoS One. 2017 Jul 7;12(7):e0181090
pubmed: 28686663
Trends Biotechnol. 2020 Apr;38(4):447-462
pubmed: 31757410
Antimicrob Agents Chemother. 2007 Jan;51(1):54-63
pubmed: 17088489
Platelets. 2021 May 19;32(4):479-491
pubmed: 32396493
J Oral Maxillofac Surg. 2018 Jul;76(7):1460-1463
pubmed: 29425752
Can Fam Physician. 2020 Sep;66(9):651-659
pubmed: 32933978
Clin Oral Investig. 2021 Nov;25(11):6309-6319
pubmed: 33842996
Curr Opin Biotechnol. 2019 Aug;58:81-91
pubmed: 30529814
Br J Ophthalmol. 2005 Sep;89(9):1097-9
pubmed: 16113356
Clin Orthop Relat Res. 2004 Oct;(427):101-6
pubmed: 15552144
Clin Oral Investig. 2021 Mar;25(3):1159-1167
pubmed: 32613433